

Preliminary Communication

Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics

A Randomized Clinical Trial

Anuoluwapo Osinusi, MD, MPH; Eric G. Meissner, MD, PhD; Yu-Jin Lee; Dimitra Bon, MS; Laura Heytens, RN; Amy Nelson, RN; Michael Sneller, MD; Anita Kohli, MD; Lisa Barrett, MD, PhD; Michael Proschan, PhD; Eva Herrmann, PhD; Bhavana Shivakumar, MS; Wenjuan Gu, PhD; Richard Kwan, PAC; Geb Teferi, MD; Rohit Talwani, MD; Rachel Silk, RN; Colleen Kotb, RN; Susan Wroblewski, RN; Dawn Fishbein, MD; Robin Dewar, PhD; Helene Highbarger, MS; Xiao Zhang, MS; David Kleiner, MD; Brad J. Wood, MD; Jose Chavez, MD; William T. Symonds, PharmD; Mani Subramanian, MD, PhD; John McHutchison, MD; Michael A. Polis, MD, MPH; Anthony S. Fauci, MD; Henry Masur, MD; Shyamasundaran Kottilil, MD, PhD

IMPORTANCE The efficacy of directly acting antiviral agents in interferon-free regimens for the treatment of chronic hepatitis C infections needs to be evaluated in different populations.

OBJECTIVE To determine the efficacy and safety of sofosbuvir with weight-based or low-dose ribavirin among a population with unfavorable treatment characteristics.

DESIGN, SETTING, AND PATIENTS Single-center, randomized, 2-part, open-label phase 2 study involving 60 treatment-naive patients with hepatitis C virus (HCV) genotype 1 enrolled at the National Institutes of Health (October 2011-April 2012).

INTERVENTIONS In the study's first part, 10 participants with early to moderate liver fibrosis were treated with 400 mg/d of sofosbuvir and weight-based ribavirin for 24 weeks. In the second part, 50 participants with all stages of liver fibrosis were randomized 1:1 to receive 400 mg of sofosbuvir with either weight-based or low-dose 600 mg/d of ribavirin for 24 weeks.

MAIN OUTCOMES AND MEASURES The primary study end point was the proportion of participants with undetectable HCV viral load 24 weeks after treatment completion (sustained virologic response of 24 weeks [SVR₂₄]).

RESULTS In the first part of the study, 9 participants (90%; 95% CI, 55%-100%) achieved SVR₂₄. In the second part, 7 participants (28%) in the weight-based group and 10 (40%) in the low-dose group relapsed after treatment completion leading to SVR₂₄ rates of 68% (95% CI, 46%-85%) in the weight-based group and 48% (95% CI, 28%-69%; $P = .20$) in the low-dose group. Twenty individuals participated in a pharmacokinetic-viral kinetic substudy, which demonstrated a slower loss rate of infectious virus in relapsers than in participants who achieved SVR (clearance, 3.57/d vs 5.60/d; $P = .009$). The most frequent adverse events were headache, anemia, fatigue, and nausea. There were 7 grade 3 events including anemia, neutropenia, nausea, hypophosphatemia, and cholelithiasis or pancreatitis. No one discontinued treatment due to adverse events.

CONCLUSION AND RELEVANCE In a population of patients with a high prevalence of unfavorable traditional predictors of treatment response, a 24-week regimen of sofosbuvir and weight-based or low-dose ribavirin resulted in SVR₂₄ rates of 68% and 48%, respectively.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01441180

JAMA. 2013;310(8):804-811. doi:10.1001/jama.2013.109309

+ Author Video Interview at jama.com

+ Supplemental content at jama.com

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Shyamasundaran Kottilil, MD, PhD, Immunopathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Room 11N204, Bethesda, MD 20892 (skottilil@niaid.nih.gov)

Chronic infection with hepatitis C virus (HCV) is a major cause of chronic liver disease, end-stage liver disease, hepatocellular cancer and remains the leading indication for liver transplants in western countries.^{1,2} The HCV epidemic in the United States is centered in large urban areas among populations with a high prevalence of unfavorable traditional predictors of treatment response.^{1,3,4} The addition of the recently approved directly acting antiviral agents telaprevir or boceprevir to pegylated interferon-alfa and ribavirin has resulted in improved sustained virologic response (SVR) rates; however, adverse reactions, high pill burdens, and drug interactions continue to make treatment challenging.⁵⁻⁷ Furthermore, certain host and viral factors including black race, advanced liver fibrosis, *IL28B* CT or TT genotypes, high baseline HCV viral loads, and prior treatment experience appear to remain associated with poorer treatment outcomes.^{5,7-9}

Recent studies show that interferon-free, directly acting antiviral agent-only regimens can successfully achieve SVR; however, populations traditionally associated with poorer treatment outcomes have been underrepresented.¹⁰⁻¹² Many

HAI *histology activity index*

HCV *hepatitis C virus*

HIV *human immunodeficiency virus*

SVR *sustained virologic response*

studies also use ribavirin, currently a standard component of interferon-based HCV therapy, which is associated with significant adverse events including hemolytic anemia, nausea, and teratogenicity.¹³ Although ribavirin clearly improves SVR rates with interferon-based therapies,^{14,15} the role and requirement for ribavirin in emerging directly acting antiviral agent regimens, including optimal dosing, have not been established.

In this study, we evaluated the safety and efficacy of sofosbuvir administered in combination with weight-based or low-dose once daily ribavirin for 24 weeks in a treatment-naive population with unfavorable characteristics of treatment success. We report the efficacy of this regimen as defined by SVR rates 24 weeks after completion of treatment as well as the host and viral factors associated with treatment relapse.

Methods

Participants

Participants were enrolled in this single-center, 2-part, randomized controlled trial conducted at the Clinical Research Center of the National Institutes of Health, Bethesda, Maryland, from October 2011 through April 2012. Eligible participants were infected with HCV genotype 1, had liver biopsy-proven chronic disease, and were naive to HCV treatment. Additional eligibility criteria included seronegativity for human immunodeficiency virus (HIV) and hepatitis B; absolute neutrophil count of 750 cells/ μ L or more; platelet count of 50 000 cells/ μ L or more; and hemoglobin of 11 g/dL or more for women and 12 g/dL or more for men. Race/ethnicity was classified as white, black, or Hispanic using patient self-reported data. Written consent was obtained from all participants except for 2 patients with limited literacy who gave oral

consent after the entire consent form had been read and explained to them.

Study Design

The study was performed in 2 parts. In the first part (proof of concept), participants with early to moderate liver fibrosis (Knodel histology activity index [HAI] fibrosis score, 0-1) were treated for 24 weeks with 400 mg/d of sofosbuvir and weight-based ribavirin (400 mg in the morning, 600 mg in the evening if <75 kg or 600 mg twice a day if >75 kg). In the second part, eligible participants with all stages of fibrosis (including compensated cirrhosis) were randomized in a balanced fashion to receive 400 mg/d of sofosbuvir in combination with either weight-based ribavirin or low-dose (600 mg/d) of ribavirin for 24 weeks. The randomization used a set of 60 random numbers, in which blocks of 4 numbers were selected. Within a block, the highest numbers were assigned to the weight-based protocol, and the lower numbers were assigned to the low-dose group. Once enrollment occurred, participants received a study number in sequential fashion. Participants who experienced treatment failure were offered the current standard of care.

Study Oversight

The study was approved by the institutional review board of the National Institute of Allergy and Infectious Diseases (NIAID) and was conducted in compliance with the Good Clinical Practice guidelines, the Declaration of Helsinki, and regulatory requirements. An independent safety monitor participated in the interim safety and efficacy analysis.

Efficacy Assessments

Plasma HCV RNA levels were measured using the real-time HCV assay (Abbott Molecular), with a lower limit of quantification of 12 IU/mL and a lower limit of detection of 3 IU/mL. The Abbott assay was used to measure HCV RNA levels in all participants at all time points. Plasma HCV RNA levels were also measured using the COBAS TaqMan HCV RNA assay, version 1.0 (Roche), with a lower limit of quantification of 43 IU/mL and a lower limit of detection of 12 IU/mL at specified clinical time points.

Safety Assessments

Adverse events and clinical laboratory results were recorded throughout the study. Adverse events were graded from 1 (mild) to 4 (severe) by a standardized scale using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (Division of AIDS toxicity table version 1.0). Patient adherence was determined by pill counts at each visit and during patient interviews. A missed dose was defined as any component of the medication regimen not taken on a given day.

Viral Kinetics, Pharmacokinetics, and Pharmacodynamics

Early viral kinetics, pharmacokinetics, and pharmacodynamics of sofosbuvir and its metabolite GS-331007 were obtained and calculated. Levels of sofosbuvir and its metabolite GS-331007 in serum were measured at 0, 1, 2, 4, 8, 12, 24, and 36

hours after administration of sofosbuvir and ribavirin using a high-performance liquid chromatography–mass spectrometry bioanalytical technique (QPS LLC).

IL28B Genotyping

Genotyping of the *IL28B* single-nucleotide polymorphism rs12979860 has been previously shown to be associated with treatment outcome.^{16,17} Whole blood was collected using PAX-gene Blood DNA tubes (Qiagen) and stored at -80°C until DNA extraction. DNA was extracted using the Paxgene Blood DNA Kit (PreAnalytiX, a Qiagen/BD Company). The *IL28B* genotype was conducted in a blinded fashion on DNA specimens using the 5' nuclease assay with *IL28B*-allele-specific TaqMan probes (ABI TaqMan allelic discrimination kit) and the ABI7500 Real-Time PCR system (Applied Biosystems). The *IL28B* genotyping was classified as either favorable (CC genotype) or unfavorable (CT or TT genotypes).¹⁸

454 Deep Sequencing for the Detection of S282T NS5B Mutation

The major mutation shown to confer resistance to NS5B drugs including sofosbuvir is an S282T mutation.¹⁹ The HCV viral RNA was extracted from baseline plasma using QIAamp Viral RNA Mini (Qiagen) followed by reverse transcription–polymerase chain reaction to amplify complementary DNA. Using the Genome Sequencer FLX system, 454 Deep sequencing was then performed in the NS5B region to determine the presence of putative resistance-associated variants to sofosbuvir, including S282T.

Liver Biopsy

All participants had undergone a liver biopsy within 3 years of enrollment, and an optional research biopsy was offered after treatment completion (within 2 weeks of drug cessation). Histopathological assessments were performed by a single pathologist in a nonblinded fashion at the time of biopsy and staged according to the Knodell-HAI scoring system.²⁰

Clinical End Points

The primary study end point was the proportion of participants with undetectable HCV viral load 24 weeks after treatment completion (SVR₂₄). Secondary efficacy end points included the proportion of participants with undetectable HCV viral load at specified time points during and after treatment. Safety end points included frequency and severity of adverse events, discontinuations due to adverse events, and safety laboratory changes.

Modeling Viral Kinetics, Pharmacokinetics, and Pharmacodynamics

Pharmacokinetics, pharmacodynamics, and viral kinetic modeling of sofosbuvir in the 20 randomized participants in the substudy were calculated using previously described techniques.^{21–23} An estimation of mean and maximum drug efficacy, infected cell loss rate, and loss rate of free virus was generated with this model.

Statistical Analysis

Although the primary interest was the per-protocol analysis, we also present the intention-to-treat analysis of all randomized par-

ticipants because these results are more readily generalizable. The per-protocol analysis included all participants who received at least 8 weeks of the study drug. For efficacy analysis, missing data points were deemed a success if the immediately preceding and subsequent time points were successful; otherwise, data points were termed as failures. Participants who had missing data due to premature discontinuations were considered failures from the point of discontinuation. Comparisons were analyzed using the nonparametric Wilcoxon rank sum test for continuous outcomes and Fisher exact test for binary outcomes. A bivariable logistic regression model of baseline characteristics was used to identify factors associated with relapse. All *P* values were 2-tailed and were considered significant only when lower than .05. Analysis was performed using PRIZM 8.0 (GraphPad Software), SAS (SAS Institute Inc), STAT-CRUNCH, and S-Plus 8.0 (Statistical Sciences Inc).

Sample size was calculated using an assumed early response rate of 90% for the weight-based group vs 85% for the low-dose group. With 50 participants, the study would be able to estimate the difference in early virologic response proportions to within plus or minus 0.18. There was a substantial gain in precision (from an accuracy of ± 0.24 to ± 0.18) from increasing the sample size from 15 to 25 per group but diminishing returns after a sample size of 25.

Results

Seventy-nine participants were screened and 60 were enrolled in this study (10 participants in part 1 [proof of concept] and 50 participants in part 2 [randomized portion]; **Figure**). All results including treatment response and safety in the 10 nonrandomized participants are shown in eTable 1 and eTable 2 in the Supplement.


Baseline Characteristics of Participants

Baseline characteristics were similar among treatment groups (**Table 1**). Eighty-three percent of the participants were black; 66%, men; and 48%, body mass index greater than 30 (calculated as weight in kilograms divided by height in meters squared); 81% had the *IL28* CT or TT genotype; 70%, GT-1a genotype; 23%, advanced liver disease; and 62%, baseline HCV RNA levels greater than 800 000.

Virologic Response

Twenty-four participants (96%) in each group achieved viral suppression by week 4. Four participants discontinued the study drug by week 8 due to nonadherence (1 in the weight-based group; 3 in the low-dose; **Figure**). One patient declined to continue study drug past week 12, but his viral load remained undetectable 24 weeks after stopping treatment. He is included in the final analysis. A total of 7 participants (28%) in the weight-based group and 10 (40%) in the low-dose group relapsed after treatment completion leading to SVR₂₄ rates of 68% (95% CI, 46%–85%) in the weight-based group and 48% (95% CI, 28%–69%; *P* = .20) in the low-dose group (**Table 2**). A within-cohort comparison of baseline factors related to SVR was performed and is shown in eTable 3 in the Supplement. Deep sequencing of all baseline samples showed no S282T resistant mutant.

Figure. Study Flow Diagram



The first 10 were sequentially enrolled from eligible participants in an open-label exploratory group. Relapse is determined at any time after end of treatment response but prior to sustained virologic response at 24 weeks. The

patient who discontinued at week 12 was still included in both analyses as having reached sustained virologic response at 24 weeks.

Viral Kinetic, Pharmacokinetic, and Pharmacodynamic Modeling

All participants experienced a rapid decline in plasma HCV RNA. A viral kinetic model over the first 50 days of treatment of all randomized participants showed no differences in viral decay based on ribavirin dose or baseline characteristics (eFigure 1 and eFigure 2 in the Supplement). However, a fully fitted pharmacokinetics-viral kinetics model of a subset of 20 participants (10 in the low-dose group and 10 in the weight-based group) showed a significantly slower loss rate of free virus (clearance) in relapsers than participants who achieved SVR (clearance, 3.57 vs 5.60 per day; $P = .009$). There were no observable differences in viral decay, drug efficiency, loss rate of infected cells, or loss rate of infectious virus based on baseline characteristics (eTable 4 in the Supplement).

Histologic Response

Twenty-nine participants (58%) had paired liver biopsies with an improvement in inflammation in 27 participants (93%) with a median drop of 5 points (15-point scale; eFigure 3A and B in the Supplement). In parallel with HCV RNA decline, there was rapid improvement of alanine aminotransferase levels with 77% normalizing by day 7 and 98% by day 14. A similar pattern was observed with aspartate aminotransferase levels (eFigure 4A).

Safety

The combination of sofosbuvir and ribavirin was safe and well tolerated with no death or discontinuation of treatment due to adverse events. The most frequent adverse events were headache, anemia, fatigue, and nausea, the severity of which ranged from

mild to moderate (Table 3). There were 7 grade 3 events. Participants in the weight-based group experienced a higher incidence of hemoglobin decline, which was maintained through week 12, than did participants in the low-dose group (week 4, 37% vs 4%; $P = .005$; week 12, 39% vs 4%; $P = .01$; eFigure 4B, in the Supplement). Eight participants (5 in the weight-based group) underwent ribavirin dose reduction for decreased hemoglobin including 3 with a history of coronary artery disease with ribavirin reduction instituted at a hemoglobin level of less than 12 g/dL. There was no use of erythropoietin-stimulating agents in this study. No major biopsy-related complications were observed.

Characteristics Associated With Relapse

Bivariable analysis of baseline factors showed that in all randomized participants who completed treatment, the odds of relapse was significantly higher in participants who were male (odds ratio [OR], 6.09; 95% CI, 1.17-31.6), had advanced fibrosis (OR, 4.27; 95% CI, 1.10-16.54), and baseline HCV RNA greater than 800 000 IU/mL (OR, 5.74; 95% CI, 1.35-24.38; Table 4). Given the small number of events and the exploratory nature of the stepwise analysis that determined variables used in the model, only the bivariable model results are reported herein.

Discussion

Although the treatment of HCV is rapidly evolving, several questions remain unanswered. This study demonstrates the effi-

Table 1. Baseline Demographics of Participants

Characteristics ^a	No. (%) of Patients		
	Part 1 of the Study, Sofosbuvir + Weight-Based Ribavirin (n = 10) ^b	Part 2 of the Study ^b	
		Sofosbuvir + Weight-Based Ribavirin (n = 25)	Sofosbuvir + Low-Dose Ribavirin (n = 25)
Age, median (IQR), y	54 (50-57)	54 (51-56)	55 (48-59)
Men	4 (40)	19 (76)	14 (56)
BMI			
Median (IQR)	26 (26-34)	28 (25-31)	30 (27-37)
≥30	3 (30)	12 (48)	14 (56)
Race/ethnicity ^c			
White	1 (10)	5 (20)	2 (8)
Black	9 (90)	18 (72)	23 (92)
Hispanic	0	2 (8)	0
<i>IL28B</i> genotype			
CC	3 (33) ^d	4 (16)	4 (16)
CT/TT	6 (67)	21 (84)	21 (84)
Knodell HAI fibrosis score			
0-1	9 (90)	19 (76)	18 (72)
3-4	1 (10)	6 (24)	7 (28)
HCV genotype 1 subtype			
1a	6 (60)	20 (80)	16 (64)
1b	4 (4)	5 (20)	9 (36)
Median baseline HCV RNA-log ₁₀ IU/mL (IQR)	6.8 (6- 7.1)	6.2 (5.4-6.4)	6.1 (5.5-6.3)
HCV RNA>800 000 IU/mL	7 (70)	16 (64)	14 (56)
Median creatinine mg/dL (IQR)	0.74 (0.64-0.95)	0.83 (0.74-0.91)	0.81 (0.72-0.94)

Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by the height in meters squared; HCV, hepatitis C virus; HAI, histology activity index fibrosis score, a low score ranges from 0-1; a high score, from 3 to 4.

^a Baseline characteristics were similar between groups except higher baseline HCV RNA in part 1 (P = .03).

^b Weight-based ribavirin: 1000-1200 mg/d, low-dose ribavirin: 600 mg/d.

^c Race was self-reported.

^d One patient who dropped out had no DNA available for *IL28B* genotyping.

Table 2. Participants With Hepatitis C Virus RNA Lower Than the Level of Quantification (Part 2)^a

Week of Treatment	Sofosbuvir+Weight-Based Ribavirin (n = 25)				Sofosbuvir+Low-Dose Ribavirin (n = 25)			
	ITT Analysis		Per-Protocol Analysis		ITT Analysis		Per-Protocol Analysis	
	No. (%) of Participants	Percentage (95% CI)	No. (%) of Participants	Percentage (95% CI)	No. (%) of Participants	Percentage (95% CI)	No. (%) of Participants	Percentage (95% CI)
24-wk Treatment								
4	24 (25)	96 (80-100)	24 (25)	96 (80-100)	24 (25)	96 (80-100)	24 (25)	96 (80-100)
8	24 (25)	96 (80-100)	24 (24)	100 (86-100)	22 (25)	88 (69-97)	22 (22)	100 (85-100)
12	24 (25)	96 (80-100)	24 (24)	100 (86-100)	22 (25)	88 (69-97)	22 (22)	100 (85-100)
24	24 (25)	96 (80-100)	24 (24)	100 (86-100)	22 (25)	88 (69-97)	22 (22)	100 (85-100)
Posttreatment								
2	21 (25)	84 (64-95)	21 (24)	88 (68-97)	15 (25)	60 (9-79)	15 (22)	68 (45-85)
4	18 (25)	72 (51-88)	18 (24)	75 (53-90)	14 (25)	56 (35-76)	14 (22)	64 (41-83)
8	17 (25)	68 (46-85)	17 (24)	71(49-87)	13 (25)	51 (31-72)	13 (22)	59 (36-79)
12	17 (25)	68 (46-85)	17 (24)	71(49-87)	12 (25)	48 (28-69)	12 (22)	55(32-76)
24	17 (25)	68 (46-85)	17 (24)	71(49-87)	12 (25)	48 (28-69)	12 (22)	55(32-76)

^a Treatment response in all participants were included in the intention-to-treat (ITT) analysis, and those who completed at least 8 weeks of treatment were included in the per-protocol analysis. The per-protocol analysis excludes all participants who stopped study medication for nonadherence to protocol

requirements (1 patient in the weight-based group at week 3, 3 patients in on low-dose group by week 8). The Roche assay was used for these time points. Weight-based ribavirin doses ranged from 1000 to 1200 mg/d and the low-dose ribavirin was 600 mg/d.

cacy of an interferon-free regimen in a traditionally difficult-to-treat population while exploring the reasons for treatment relapse. In this study, treatment of chronic HCV infection with a single directly acting antiviral agent (sofosbuvir) and weight-

based ribavirin resulted in a high SVR rate in a population with unfavorable traditional predictors of treatment response compared with reported rates with currently used interferon-based therapy in similar populations.^{7,8} Compared with previ-

Table 3. Incidence of Adverse Events During the Study Part 2 Treatment Period

Adverse Events ^b	No. (%) of Events Among Patients Taking Sofosbuvir	
	Plus Weight-Based Ribavirin (n = 25) ^a	Plus Low-Dose Ribavirin (n = 25) ^a
Death	0	0
Any serious adverse event	0	1 (4)
Any grade 3-4 event ^c	1 (4)	5 (20)
Any discontinuation owing to an adverse event	0	0
Ribavirin dose reduction	5 (20)	3 (12)
Headache	7 (28)	7 (28)
Anemia	8 (32)	4 (16)
Fatigue	4 (16)	6 (24)
Nausea	4 (16)	5 (20)
Dyspnea	2 (8)	2 (8)
Vomiting	1 (4)	3 (12)
Dizziness	2 (8)	1 (4)
Pruritic rash	2 (8)	0
Myalgia	0	2 (8)
Laboratory abnormality		
Anemia grade (range), g d/L		
1 (10.0-10.9)	6 (24)	3 (12)
2 (9.0-9.9)	2 (8)	0
3 (7.0-8.9)	0	1 (4)
Hyperbilirubinemia grade (range), × ULN		
1 (1.1-1.5)	4 (16)	2 (8)
2 (1.6-2.5)	3 (12)	1 (4)
3 (2.5-5)	1 (4)	0
Hypophosphatemia grade (range), mg/dL		
2 (2.0-2.4)	6 (24)	6 (24)
3 (1.0-1.9)	0	2 (8)
Neutropenia		
Grade 3 (range, 500-749/μL)	0	1 (4)
Hypocalcemia, <2.04 mmol/L	6 (24)	5 (20)
Hypomagnesemia, <0.63 mmol/L	0	1 (4)
Elevated serum creatinine, >1.1 × ULN	1 (4)	3 (12)

Abbreviation: ULN, upper limit of normal.

^a Weight-based ribavirin doses ranged from 1000 to 1200 mg/d and the low-dose ribavirin was 600 mg/d.

^b All adverse events experienced by least 2 participants in any group are included regardless of relatedness to study drug.

^c Grade 3 events included neutropenia in a patient with a baseline absolute neutrophil count of 850, 1 patient who had a hemoglobin less than 9 g/dL after undergoing abdominoplasty, 1 patient whose nausea resolved within 48 hours, and 2 patients with hypophosphatemia lower than 1.9 mg/dL. One morbidly obese patient who had experienced developed cholelithiasis with elevated lipase and transient pancreatitis 3 weeks after completion of study drug. This issue was resolved with elective cholecystectomy and was not considered related to study drug.

ous trials testing boceprevir and telaprevir, this population had a higher prevalence of unfavorable traditional predictors of treatment response including black race (80% vs 7%-15%); genotype 1a (70% vs 60%-64%); advanced fibrosis (24% vs 9%-20%); and body mass index greater than 30 (49% vs 22%).^{7,8} The overall SVR rate achieved by participants who received sofosbuvir in combination with weight-based ribavirin in our study was 68% compared with the 84% reported in a recent New Zealand study of sofosbuvir and weight-based ribavirin in a predominantly white, treatment-naive population.¹¹ Because treatment of HCV is evolving from an interferon-based combination therapy to an all-oral, interferon-free directly acting antiviral agent regimen, these results are encouraging and provide important information regarding the expected treatment responses in a population representative of the US epidemic.

In an exploratory bivariable model, we found that the baseline factors of male sex, advanced liver disease, and high baseline HCV RNA were associated with relapse. The association of advanced liver disease with higher odds of relapse is similar to that described with direct-acting antiviral agent inter-

feron-based regimens.⁶⁻⁸ In this regard, 7 of the 13 participants (54%) with advanced liver fibrosis treated in this study relapsed including all 4 participants with cirrhosis. Future studies are warranted to evaluate the efficacy of sofosbuvir and ribavirin regimens in participants with advanced fibrosis.

There were no cases of viral breakthrough while receiving therapy in participants treated with sofosbuvir and ribavirin similar to what has been reported in prior studies.¹¹ Comprehensive analysis of baseline plasma HCV quasi-species by 454 deep sequencing failed to detect the characteristic S282T mutants previously associated with resistance to sofosbuvir.

The kinetics of HCV decline during interferon and ribavirin therapy has been previously described as a predictor of SVR.^{21,22} Because interferon-free directly acting antiviral agent therapy is entirely based on achieving maximum suppression of HCV replication, we sought to explore the effect of early HCV viral kinetics, pharmacokinetics, and pharmacodynamics on therapeutic response. Although there were no significant differences in viral kinetics or pharmacokinetics between the weight-based ribavirin and low-dose ribavirin

Table 4. Bivariable Model of Treatment Relapse Based on Baseline Characteristics^a

Baseline Characteristic	No. of Patients		Effect	Odds Ratio (95% CI)	P Value
	With Relapse	Total			
Ribavirin dose					
Low dose	10	22	Low dose vs weight based rate	2.02 (0.60-6.83)	.26
Weight based	7	24			
Age, y					
>50	14	35	>50 vs ≤50	1.78 (0.40-7.88)	.45
≤50	3	11			
Genotype					
1a	11	34	1a vs 1b	0.48 (0.12-1.83)	.28
1b	6	12			
Race					
Black	15	38	Black vs nonblack	1.96 (0.35-11.01)	.45
Nonblack	2	8			
Sex					
Men	15	31	Men vs women	6.09 (1.17-31.61)	.03
Women	2	15			
IL28B genotype					
CT/TT	15	40	CT/TT vs CC	1.20 (0.196-7.36)	.84
CC	2	6			
BMI					
>30	6	24	>30 vs ≤30	0.33 (0.10-1.16)	.08
≤30	11	22			
Knodell HAI fibrosis score					
3-4	8	13	3-4 vs 0-2	4.27 (1.10-16.54)	.04
0-2	9	33			
HCV RNA					
>800 000	14	27	>800 000 vs ≤800 000	5.74 (1.35-24.38)	.02
≤800 000	3	19			

Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; HAI, histology activity index.

^a Univariate analysis of baseline factors showed that in all randomized participants who completed treatment, the odds of relapse was significantly higher in participants who were men, had advanced fibrosis, and had baseline HCV RNA >800 000 IU/mL.

groups, the viral kinetics-pharmacodynamics model demonstrated a significantly slower loss rate of infectious virus in participants who subsequently relapsed. The mechanism of viral relapse in these participants remains elusive and future research will be focused on identifying the biological basis for incomplete clearance of HCV in these participants.

Limitations of this study include the relatively small sample size in each group and a higher, though small, increase in the number of discontinuations with low-dose ribavirin. Due to the small size, associations described are preliminary in nature and require further evaluation in larger studies. Ribavirin is associated with significant adverse events^{13,23} but appears to be essential for optimal response to interferon-based and certain directly acting antiviral agent therapies.^{11,14,15} Although our study did not show a significant association between treatment re-

sponse and ribavirin dosing, it remains important to determine the optimal dose and role of ribavirin in the treatment of chronic HCV infection in larger interferon-free studies.

In conclusion, treatment with a 24-week regimen of sofosbuvir and ribavirin resulted in an SVR rate of 68% in the weight-based ribavirin regimen and 48% in the low-dose ribavirin regimen among patients with chronic HCV and unfavorable traditional predictors of treatment response who are representative of the demographics of the US HCV epidemic. The delineation of the host and viral factors associated with treatment relapse with different directly acting antiviral agent interferon-free regimens needs to be further assessed. As new direct-acting antiviral agent regimens are being evaluated, it is important that these studies involve populations most affected by the disease.

ARTICLE INFORMATION

Author Affiliations: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (Osinusi, Meissner, Lee, Nelson, Sneller, Kohli, Barrett, Shivakumar, Wroblewski, Zhang, Polis, Fauci, Kottlilil); Clinical Research Directorate/Clinical Monitoring Research Program, Science Applications International Corp (SAIC)-Frederick Inc, Frederick National Laboratory

for Cancer Research, Frederick, Maryland (Osinusi, Silk, Kotb); Institute of Biostatistics and Mathematical Modeling, Johann Wolfgang Goethe University, Frankfurt, Germany (Bon, Herrmann); Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, Maryland (Heytens, Kwan, Masur); Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,

Maryland (Proschan); SAIC-Frederick Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland (Gu, Dewar, Highbarger); Unity Health Care Inc, Washington, DC (Teferi, Chavez); Department of Infectious Diseases, University of Maryland, Baltimore (Taiwani); Department of Infectious Diseases, MedStar Washington Hospital Center, Washington, DC (Fishbein); Department of Pathology, National Cancer Institute, Bethesda, Maryland (Kleiner); Center for Interventional

Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Bethesda, Maryland (Wood); Gilead Sciences, Foster City, California (Symonds, Subramanian, McHutchison).

Author Contributions: Drs Kottlil and Osinusi had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Osinusi, Meissner, Heytens, Sneller, Kohli, Fishbein, Symonds, McHutchison, Polis, Fauci, Masur, Kottlil.

Acquisition of data: Osinusi, Meissner, Heytens, Nelson, Sneller, Kohli, Barrett, Kwan, Teferi, Talwani, Silk, Kotb, Wroblewski, Dewar, Highbarger, Zhang, Kleiner, Wood, Chavez, Polis, Masur, Kottlil.

Analysis and interpretation of data: Osinusi, Meissner, Lee, Bon, Nelson, Kohli, Barrett, Proschan, Herrmann, Shivakumar, Gu, Kwan, Zhang, Kleiner, Wood, Symonds, Subramanian, McHutchison, Polis, Fauci, Masur, Kottlil.

Drafting of the manuscript: Osinusi, Meissner, Lee, Bon, Nelson, Gu, Masur, Kottlil.

Critical revision of the manuscript for important intellectual content: Osinusi, Meissner, Bon, Heytens, Sneller, Kohli, Barrett, Proschan, Herrmann, Shivakumar, Teferi, Talwani, Silk, Kotb, Wroblewski, Fishbein, Dewar, Highbarger, Zhang, Kleiner, Wood, Chavez, Symonds, Subramanian, McHutchison, Polis, Fauci, Masur, Kottlil.

Statistical analysis: Osinusi, Bon, Proschan, Herrmann, Shivakumar, Gu, Polis.

Obtained funding: Masur, Kottlil.

Administrative, technical, or material support:

Osinusi, Lee, Heytens, Nelson, Sneller, Kohli, Barrett, Kwan, Teferi, Silk, Kotb, Wroblewski, Fishbein, Dewar, Highbarger, Zhang, Wood, Symonds, McHutchison, Polis, Masur, Kottlil.

Study supervision: Osinusi, Kohli, Barrett, Kwan, Fishbein, Wood, McHutchison, Polis, Fauci, Masur, Kottlil.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Herrmann reported that she served as research consultant of Roche Pharma and Novartis. Dr Teferi reported that he serves on the Gilead and Merck Advisory Boards and as a speaker for Gilead. Dr Talwani reported that he has served as a speaker for Merck and performs research funded by Vertex pharmaceuticals. Dr Chavez reported that he is a member of the Regional Advisory Boards for Abbott and Gilead. Drs Symonds, Subramanian, and McHutchison are employees of Gilead Pharmaceuticals. No other disclosures were reported.

Funding/Support: This project was funded in whole by grant HHSN261200800001E from the National Cancer Institute, National Institutes of Health. This research was supported in part by the National Institute of Allergy and Infectious Diseases and by the German Research Foundation by the clinical research unit KFO 129. Pharmasset Pharmaceuticals and subsequently Gilead Sciences provided sofosbuvir and scientific advice.

Role of the Sponsor: The Regulatory Compliance and Human Participants Protection Branch of the National Cancer Institute, National Institutes of Health (NIAID) served as the study sponsor and was involved in the review and approval of the study via the usual peer-review process as well as the study management. The Regulatory Compliance and

Human Participants Protection Branch played no role in the design of the study, data collection, or analysis; interpretation of the data; preparation of the manuscript; or the decision to submit the manuscript for publication.

Disclaimer: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government.

Previous Presentations: The data from this study have been partially presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, Boston, Massachusetts; November 13, 2012, and at the 20th Conference on Retroviruses and Opportunistic Infections, CROI 2013, Atlanta, Georgia; March 4, 2013.

Additional Contributions: We thank Katie Watkins BS, Erin Pojunas, BS, and Susan Vogel, RN, BSN (clinical monitoring support), Judith Starling, PharmD (pharmacy), Ashton Shaffer, BS (*IL28B* genotyping), Michelle Chakrabarti, BS, Jerome Pierson, PhD, John Tierney, BSN, MPM (regulatory support); William Ronnenberg, JD, MIP, MS, Richard Williams, PhD, and Mike Mowatt, PhD (technology transfer support); Barry Egel, MD, CPI (sponsor medical monitor), John Powers, MD (oversight), and Kenneth Sherman, MD, PhD (independent medical monitor), for their contributions. None have received compensation for their participation.

REFERENCES

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med.* 2006;144(10):705-714.
2. Kim WR. The burden of hepatitis C in the United States. *Hepatology.* 2002;36(5)(suppl 1):S30-S34.
3. Ly KN, Xing J, Klevans RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med.* 2012;156(4):271-278.
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med.* 1999;341(8):556-562.
5. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med.* 2011;364(13):1207-1217.
6. McHutchison JG, Everson GT, Gordon SC, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med.* 2009;360(18):1827-1838.
7. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med.* 2011;364(13):1195-1206.
8. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med.* 2011;364(25):2405-2416.
9. McHutchison JG, Manns MP, Muir AJ, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection [published correction
10. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. *N Engl J Med.* 2013;368(1):45-53.
11. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med.* 2013;368(1):34-44.
12. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. *N Engl J Med.* 2012;366(3):216-224.
13. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 1995;123(12):897-903.
14. McHutchison JG, Gordon SC, Schiff ER, et al; Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med.* 1998;339(21):1485-1492.
15. Poynard T, Marcellin P, Lee SS, et al; International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks vs interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet.* 1998;352(9138):1426-1432.
16. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature.* 2009;461(7262):399-401.
17. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology.* 2010;139(1):120; e18.
18. Neukam K, Barreiro P, Rivero-Juárez A, et al. Pegylated interferon plus ribavirin is suboptimal in *IL28B* CC carriers without rapid response. *J Infect.* 2013;67(1):59-64.
19. Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. *Antimicrob Agents Chemother.* 2008;52(12):4356-4369.
20. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology.* 1981;1(5):431-435.
21. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. *Hepatology.* 2007;46(1):16-21.
22. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. *Hepatology.* 2003;37(6):1351-1358.
23. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology.* 1997;26(2):473-477.